Graphite Bio Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Kim Drapkin

Geschäftsführender

US$624.4k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	32.1%
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kim Drapkin im Vergleich zu den Einnahmen von Graphite Bio verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	US$624k	US$201k	-US$125m

Vergütung im Vergleich zum Markt: KimDie Gesamtvergütung ($USD624.39K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.58M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Kim mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Kim Drapkin (55 yo)

less than a year

Amtszeit

US$624,385

Vergütung

Ms. Kimberlee Cobleigh Drapkin, also known as Kim, CPA, was an Independent Director of Graphite Bio, Inc. since August 03, 2023 and serves as its President, Chief Executive Officer and Principal Executive,...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kimberlee Drapkin	President	less than a year	US$624.39k	keine Daten
Matthew Porteus	Academic Founder & Director	4yrs	US$148.40k	6.06% $ 11.5m
Perry Karsen	Independent Chairman of the Board	3.8yrs	US$112.02k	0.28% $ 536.4k
Joseph Jimenez	Independent Director	3.8yrs	US$84.90k	0.28% $ 529.5k
Kristen Hege	Independent Director	2.9yrs	US$83.40k	0% $ 0
Jerel Davis	Independent Director	4.4yrs	US$84.90k	0% $ 0
Carlo Rizzuto	Independent Director	4yrs	US$83.40k	0% $ 0
Smital Shah	Independent Director	2.9yrs	US$88.40k	0.010% $ 19.2k
Joanne Viney	Independent Director	3yrs	US$83.40k	0% $ 0
Abraham Bassan	Independent Director	3.8yrs	US$83.40k	0% $ 0

3.8yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrener Vorstand: GRPHDie Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).

Graphite Bio Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Graphite Bio, Inc. Announces Executive Changes

Graphite Bio, Inc. Appoints Kimberlee C. Drapkin as Independent Director

Graphite Bio, Inc Announces Departure of Alethia Young as Chief Financial Officer

Graphite Bio, Inc., Annual General Meeting, Jul 19, 2023

High number of new and inexperienced directors

Graphite Bio, Inc., Annual General Meeting, Jun 21, 2022

Recent updates

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from NASDAQ Composite Index

New major risk - Share price stability

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

LENZ Therapeutics, Inc. entered into a definitive merger agreement to acquire Graphite Bio, Inc. (NasdaqGM:GRPH) for approximately $230 million in a reverse merger transaction.

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Announces Executive Changes

Graphite Bio, Inc. Appoints Kimberlee C. Drapkin as Independent Director

Graphite Bio, Inc Announces Departure of Alethia Young as Chief Financial Officer

Graphite Bio, Inc., Annual General Meeting, Jul 19, 2023

We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely

Price target decreased by 23% to US$2.83

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio, Inc. Announces Voluntary Pause of Phase 1/2 Cedar Study of Nulabeglogene Autogedtemcel (Nula-Cel) for Sickle Cell Disease

Price target decreased to US$10.86

Graphite Bio, Inc. Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

Graphite Bio doses first patient with GPH101 for sickle cell disease

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from Russell 2500 Value Index

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio: Selling For Much Less Than Net Cash

Graphite Bio, Inc. Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25 Annual Meeting

Graphite Bio, Inc., Annual General Meeting, Jun 21, 2022

High number of new and inexperienced directors

Graphite Bio, Inc. Announces Management Changes

Graphite Bio, Inc. Announces Executive Changes

High number of new and inexperienced directors

Graphite Bio, Inc. Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

Graphite Bio: An Important Stock To Track In The Gene Editing Space

Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans

Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr

Graphite Bio, Inc. has completed an IPO in the amount of $238 million.

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter